Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1685 of 5804
-
New HIV drug combo studied in kids for better virus control
Disease control OngoingThe goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in children (age ≥ 4 weeks to \< 18 years) with HIV.
Phase: PHASE2, PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to beat Cancer-Related insomnia
Symptom relief OngoingThis randomized phase II trial studies how well cognitive behavioral therapy and multimodal therapy works in treating sleep disturbance in patients with cancer. Cognitive behavioral therapy may help reduce sleep disturbances, fatigue, and insomnia as well as improve the well-bein…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Old drug, new hope? spironolactone trial targets lung blood vessel damage
Disease control Recruiting nowBackground: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high. Lung blood vessel function can be harmed by progressive injuries, such as infl…
Phase: PHASE2 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Weekly carfilzomib combo shows promise for elderly myeloma patients
Disease control CompletedIFM 2012-03 protocol is a Phase 2 multicenter nonrandomized open in elderly patients with multiple myeloma at diagnosis. Study primary objectives are in the first step to determine Maximum tolerated dose (MTD) of Carfilzomib Weekly based on definition of Dose-limiting toxicities …
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Parkinson's drug pump could smooth out daily 'Off' episodes
Disease control CompletedThis is a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics (PK) of ND0612 in Parkinson's disease (PD) patients on an optimized oral levodopa (LD) regimen and experiencing ≥2 h/day of OFF time. Safety and tolerability, PK prof…
Phase: PHASE2 • Sponsor: NeuroDerm Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Vitamin c boost: could a simple supplement make pancreatic cancer treatment safer?
Disease control CompletedThis is a phase 1 (first in man) study testing the safety of adding high dose ascorbate (vitamin C) to standard radiation and chemotherapy for treatment of pancreatic cancer.
Phase: PHASE1 • Sponsor: Joseph J. Cullen • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New study tests better way to freeze away heart rhythm problem
Disease control CompletedCryoballoon ablation has emerged as a safe and effective strategy for treatment of atrial fibrillation (AF) for which it has recently received a 'first-line' therapy indication by the FDA. Pulmonary vein (PV) isolation (PVI) has been the cornerstone of this procedure achieving fr…
Sponsor: Sacramento EP Research • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Heart surgery drug shows promise in cutting lung complications
Disease control CompletedThis study investigates the association between intraoperative ulinastatin administration and PPCs incidence in cardiac surgery. It comprises three core components: an innovative retrospective analysis, a bioinformatics study integrating network pharmacology and molecular docking…
Sponsor: Qin Zhang • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New malaria vaccine candidate moves to human safety tests
⭐️ VACCINE ⭐️ CompletedThe primary objective is to evaluate the safety of 3 doses given at D0, W4, and W26 of 50 µg dosage of AMA1-DiCo adjuvanted either with GLA-SE or Alhydrogel® in healthy European adults not previously exposed to the parasite P.falciparum and in healthy African adults exposed to th…
Phase: PHASE1 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:01 UTC
-
New hope against Drug-Resistant lung infection?
Disease control ENROLLING_BY_INVITATIONThe objective of this clinical trial is to evaluate the correlation between clinical efficacy and safety of omadacycline in the treatment of Mycobacterium abscessus infection through retrospective cohort studies. The main questions it aims to answer include: Clinical efficacy of …
Sponsor: Beijing Chest Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Sound waves could push kidney stones out without surgery
Symptom relief OngoingThis study tests moving kidney stones using focused ultrasound (referred to as ultrasonic propulsion). The study includes multiple population groups to investigate the ability of our technology to: a) move stone fragments to a location within the kidney to improve their chances o…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Brain pacemaker tested for untreatable depression
Disease control OngoingWe propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients with treatment refractory depression (TRD). Data from the University of Bonn indicates that surgical lesions of the medical forebrain bundle can produce therapeutic benefits in patients with …
Phase: NA • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could adding an antibody boost a standard CLL drug?
Disease control OngoingThis phase II trial studies ibrutinib with or without rituximab in treating patients with chronic lymphocytic leukemia that has come back after treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with mono…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Special oil may tame seizures in rare brain energy disorder
Disease control CompletedThe purpose of this project is to study the efficacy of triheptanoin oil in patients with GLUT1 deficiency syndrome.
Phase: PHASE2 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug combo shows promise for rare lymphoma
Disease control OngoingSingle arm phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal s…
Phase: PHASE2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New stem cell transplant option for patients without a perfect donor match
Disease control Recruiting nowThe goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease f…
Phase: EARLY_PHASE1 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Premature baby brain drug fails in large trial
Disease control CompletedRecombinant human erythropoietin (Epo) is a promising novel neuroprotective agent. Epo decreases neuronal programmed cell death resulting from brain injury; it has anti-inflammatory effects, increases neurogenesis, and protects oligodendrocytes from injury. We hypothesize that n…
Phase: PHASE3 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo shows promise for rare eye cancer
Disease control OngoingThis randomized phase II trial studies how well trametinib with or without Akt inhibitor GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to other parts of the body (metastatic). Trametinib and GSK2141795 may stop the growth of tumor cells by…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Exercise program shows promise for diabetic nerve damage
Disease control CompletedType 2 diabetes (DM2) affects nearly 20 million people in the United States while impaired glucose regulation (IGR), which includes impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and early diabetes affects a considerably larger but unknown population group. At …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New immune therapy combo aims to tame chronic GVHD in Steroid-Resistant patients
Disease control OngoingThis research study is a Phase I clinical trial, which tests the safety of an investigational combination of IL-2 plus donor anti-inflammatory Treg cells and also tries to define the appropriate dose of the investigational combination of IL-2 plus donor anti-inflammatory Treg cel…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC